
Sanofi to acquire Translate Bio
Sanofi has acquired Translate Bio as part of its endeavour to accelerate the application of mRNA to develop therapeutics and vaccines. Under the agreement, Sanofi will acquire all outstanding shares for a total equity value of approximately $3.2 billion (on a fully diluted basis). “Translate Bio adds an mRNA technology… Read More















